Designing drugs with reversible activity
Crossref DOI link: https://doi.org/10.1038/s41587-024-02242-y
Published Online: 2024-04-30
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Neri, Dario
Text and Data Mining valid from 2024-04-30
Version of Record valid from 2024-04-30
Article History
First Online: 30 April 2024
Competing interests
: D.N. is co-founder, CEO and shareholder of Philogen, a biotech company that works (among other things) in the field of DNA-encoded chemical libraries.